Abstract CT221: CHRONOS-3: A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of phosphatidylinositol-3 kinase (PI3K) alpha/delta inhibitor copanlisib in combination with rituximab in patients with relapsed indolent B-c

Mapping Intimacies ◽

10.1158/1538-7445.am2015-ct221 ◽

2015 ◽

Author(s):

Pier Luigi Zinzani ◽

John F. Gerecitano ◽

Marius Giurescu ◽

Rodrigo Ito ◽

Katharina Mueller ◽

...

Keyword(s):

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Phosphatidylinositol 3 Kinase ◽

Double Blind ◽

Double Blind Placebo ◽

Phosphatidylinositol 3

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)

Cardiovascular Drugs and Therapy ◽

10.1007/s10557-011-6304-x ◽

2011 ◽

Vol 25 (S1) ◽

pp. 33-45 ◽

Cited By ~ 91

Author(s):

Masunori Matsuzaki ◽

◽

Masatsugu Hori ◽

Tohru Izumi ◽

Masatake Fukunami

Keyword(s):

Heart Failure ◽

Standard Treatment ◽

Volume Overload ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Heart Failure Patients

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725768310.793547377 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01860-7 ◽

2021 ◽

Vol 21 ◽

pp. S376-S377

Author(s):

Umberto Vitolo ◽

Grzegorz S. Nowakowski ◽

John M. Burke ◽

Christopher P. Fox ◽

Marek Trneny ◽

...

Keyword(s):

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase Iii ◽

Controlled Study ◽

Newly Diagnosed ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

LB03A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT OR PLACEBO ON STANDARD OF CARE IN PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfy146.lb03 ◽

2018 ◽

Vol 33 (suppl_1) ◽

pp. i636-i637

Author(s):

David Jayne ◽

Mary Dooley ◽

David Wofsy ◽

Tsutomo Takeuchi ◽

Ana Malvar ◽

...

Keyword(s):

Lupus Nephritis ◽

Standard Of Care ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Class Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Active Class

Download Full-text

No. 128 Efficacy and Safety of AbobotulinumtoxinA in the Treatment of Cervical Dystonia: A Phase III Randomized Double-Blind Placebo-Controlled Study

PM&R ◽

10.1016/j.pmrj.2014.08.256 ◽

2014 ◽

Vol 6 (8) ◽

pp. S122

Author(s):

Philippe Picaut ◽

Werner Poewe ◽

Katalin Bihari ◽

Marta Banach

Keyword(s):

Cervical Dystonia ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.15733 ◽

2020 ◽

Author(s):

Seong Jun Seo ◽

Bong Seok Shin ◽

Joo‐Heung Lee ◽

Haeyoun Jeong

Keyword(s):

Plaque Psoriasis ◽

Korean Population ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Annals of the Rheumatic Diseases ◽

10.1136/ard.2007.080002 ◽

2008 ◽

Vol 67 (8) ◽

pp. 1096-1103 ◽

Cited By ~ 335

Author(s):

M Schiff ◽

M Keiserman ◽

C Codding ◽

S Songcharoen ◽

A Berman ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Inadequate Response ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )

British Journal of Dermatology ◽

10.1111/bjd.19147 ◽

2020 ◽

Vol 183 (2) ◽

pp. 231-241 ◽

Cited By ~ 8

Author(s):

A.S. Paller ◽

M.M.B. Seyger ◽

G. Alejandro Magariños ◽

J. Bagel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Paediatric Patients

Download Full-text

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-207654 ◽

2015 ◽

Vol 75 (2) ◽

pp. 332-340 ◽

Cited By ~ 111

Author(s):

J T Merrill ◽

R F van Vollenhoven ◽

J P Buyon ◽

R A Furie ◽

W Stohl ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text